Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DBV Technologies expands its scientific advisory board

This article was originally published in Scrip

Executive Summary

DBV Technologies (France), a biopharmaceutical company focused on the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, has expanded its scientific advisory board with the appointments of Professor Gideon Lack and Associate Professor Philippe Eigenmann. Professor Lack is head of the children’s allergy service at Guy's and St Thomas' NHS Foundation Trust and a professor of paediatric allergy at King's College, London, while Professor Eigenmann is an associate professor at the department of infants and adolescents at the Hospital cantonal Universitaire Genève, Switzerland, specialising in paediatric allergy diagnosis and treatment.

You may also be interested in...

‘FDA Is Not the Villain:’ Study Highlights Need For Post-Market Focus To Spur Antibiotics

A study of drug approvals over more than three decades shows antimicrobials, including antibacterials, had consistently shorter development and review times than other types of products. While antibacterials were less likely to participate in special US FDA programs designed to help along review, experts said reimbursement reform, not new regulatory flexibility, is needed to help address the crisis of drug-resistant infections. 

Hahn: Expect More Telemedicine Promos, Public Service Messages On COVID-19 Protection From FDA

US FDA commissioner Stephen Hahn emphasized the important role that telemedicine, COVID-19 testing, and agency-reviewed face masks and ventilators have played during the pandemic in a 1 June speech.

Zimmer Settles Joint-Implant Patent Case For $9.6M

Zimmer Biomet has agreed to pay $9.6m to Conformis Inc. to resolve a dispute over personalized joint replacement technology.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts